Eversept Partners LP Makes New $2.36 Million Investment in Lipocine Inc. $LPCN

Eversept Partners LP acquired a new position in Lipocine Inc. (NASDAQ:LPCN) in the first quarter, Holdings Channel.com reports. The firm acquired 294,989 shares of the specialty pharmaceutical company’s stock, valued at approximately $2,357,000.

Several other institutional investors have also recently modified their holdings of the company. Squadron Capital Management LLC purchased a new position in shares of Lipocine during the 4th quarter valued at about $4,256,000. Diadema Partners LP bought a new stake in Lipocine in the 4th quarter worth approximately $2,095,000. AIGH Capital Management LLC purchased a new stake in Lipocine in the first quarter worth approximately $1,598,000. Ikarian Capital LLC purchased a new stake in Lipocine in the fourth quarter worth approximately $1,602,000. Finally, Persistent Asset Partners Ltd bought a new position in Lipocine during the fourth quarter valued at approximately $567,000. 9.11% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Several research analysts have commented on the stock. Weiss Ratings downgraded shares of Lipocine from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Thursday, June 18th. Wall Street Zen raised shares of Lipocine from a “sell” rating to a “hold” rating in a research note on Saturday, July 18th. Finally, HC Wainwright reaffirmed a “neutral” rating on shares of Lipocine in a report on Monday, April 6th. One analyst has rated the stock with a Strong Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $15.00.

Lipocine Trading Up 2.9%

LPCN opened at $2.14 on Tuesday. Lipocine Inc. has a 12 month low of $1.81 and a 12 month high of $12.37. The business’s 50-day moving average price is $2.29 and its 200-day moving average price is $5.10. The company has a market cap of $17.63 million, a P/E ratio of -1.14 and a beta of 0.44.

Lipocine (NASDAQ:LPCN) last issued its earnings results on Thursday, May 7th. The specialty pharmaceutical company reported ($0.54) earnings per share for the quarter, missing the consensus estimate of ($0.51) by ($0.03). Lipocine had a negative net margin of 571.18% and a negative return on equity of 66.70%. The company had revenue of $0.12 million for the quarter, compared to analysts’ expectations of $0.16 million. Equities research analysts forecast that Lipocine Inc. will post -1.91 earnings per share for the current fiscal year.

Lipocine Profile

Lipocine Inc is a clinical-stage pharmaceutical company focused on the development and commercialization of oral drug delivery technologies. The company’s core expertise lies in lipid-based formulations designed to improve the bioavailability of therapeutics that traditionally require injectable administration. By leveraging proprietary technologies, Lipocine aims to offer patient-friendly alternatives with the potential for more consistent pharmacokinetic profiles and improved compliance.

The company’s lead product, TLANDO (LPCN 1021), is an oral testosterone replacement therapy approved by the U.S.